Annual General Meeting of CombiGene 2019
Today, 16 May 2019, CombiGene AB (publ) held its Annual General Meeting (“AGM”) in Lund. Below follows a summary of the resolutions by the AGM. All decisions were made with the required majority.
The AGM resolved to adopt the profit and loss account and the balance sheet as well as the consolidated profit and loss account and the consolidated balance sheet. Furthermore, the AGM resolved that no dividend is to be paid for the financial year 2018.
Resolution on discharge from liability for the Board Members and the CEO
The AGM resolved to discharge the Board Members and the CEO from liability for the financial year 2018.
The Board of Directors, auditor and remuneration
The Board Members Arne Ferstad, Peter Nilsson, Lars Thunberg and Susana Ayesa Alvarez were re-elected and Hilde Furberg was elected as a new Board Member. Morten Albrechtsen declined to be re-elected. Arne Ferstad was re-elected Chairman of the Board. The AGM resolved that remuneration to the Board of Directors will be SEK 175,500 to the Chairman of the Board and SEK 114,400 each to the Board Members. The chartered accountants Thomas Axelsson and Fatima Smiding were re-elected as auditors. The chartered accountant Joakim Paulson was re-elected as deputy auditor. The AGM resolved that remuneration to the auditors will be paid according to approved invoice.
Resolution on authorisation for the Board of Directors to issue shares, convertibles or warrants
The AGM authorised the Board of Directors, in accordance with the proposal in the notice, to issue new shares, convertibles or warrants on one or more occasions prior to the next AGM, with or without regard to shareholders’ pre-emption rights. The payment of issued shares may be in cash, by non-cash consideration or by set-off.
CombiGene’s vision is to provide patients affected by severe life-altering diseases with the prospect of a better life through novel gene therapies. CombiGene’s business concept is to develop effective gene therapies for severe life-altering diseases where adequate treatment is currently lacking. Development assets are sourced from an external research network and developed to achieve clinical proof of concept. Drug candidates for common diseases will be co-developed and commercialized through strategic partnerships, while the company may manage this process on its own for drugs targeting niched patient populations. The company is public and listed on the Swedish marketplace Nasdaq First North Growth Market and the company’s Certified Advisor is FNCA Sweden AB, +46 (0)852 80 03 99 email@example.com.